November 16, 2023 | Autonomix

Newsroom

Stay up to date with the latest news about Autonomix.

Autonomix Medical, Inc. Announces Appointment of Christopher C. Capelli, M.D. to Board of Directors

“We are pleased to welcome Dr. Capelli to our board of directors. He brings with him a wealth of knowledge and expertise, amassed over a noteworthy career. We believe Dr. Capelli will undoubtably be a valuable part of the team as we continue to advance the Company and our novel approach to how diseases involving the peripheral nervous system are diagnosed and treated,” commented Lori Bisson, Chief Executive Officer of Autonomix.

Stay Up-to-Date With The Future of Autonomix

Autonomix Medical, Inc.
21 Waterway Ave, Suite 300
The Woodlands, TX 77380

LEGAL DISCLAIMER
This presentation (the “presentation”) has been prepared for use by Autonomix Medical, Inc. (“Autonomix”) in connection with their proposed offering. This presentation is for information purposes only and is being provided to assist interested parties in making their own evaluation with respect to a potential investment, and for no other purpose. This presentation may not be reproduced or redistributed, in whole or in part, without the prior written consent of Autonomix. Autonomix does not make any representation or warranty as to the accuracy or completeness of the information contained in this presentation. This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in connection with the proposed offering and is not intended to form the basis of any investment decision. You should consult your own legal, regulatory, tax, business, financial and accounting advisors to the extent you deem necessary and must make your own investment decision and perform your own independent investigation and analysis of an investment in the transactions contemplated in this presentation.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION (“SEC”) NOR ANY STATE OR TERRITORIAL SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESENTATION IS TRUTHFUL OR COMPLETE.

FORWARD-LOOKING STATEMENTS
This presentation may include ‘’forward-looking statements.‘’ To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Autonomix Medicial, Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’

Although Autonomix Medical Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Autonomix are highly speculative. Investing in shares of Autonomix involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.

Autonomix intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Autonomix, the offering and any other related topics, please review the registration statement that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.

USE OF DATA
The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. Autonomix assumes no obligation to update the information in this presentation.